Pyxis Oncology, Inc.

NASDAQ:PYXS

Biotechnology

Healthcare
$1.41 +5.53%

+$0.11 today

Market cap
$168.65M
Beta
1.43
P/E (TTM)
-1.6
EPS (TTM)
-$1.29
52W Low $0.97High $5.55

Volume 0.75M

Average 0.50M

PYXS Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Pyxis Oncology, Inc.NASDAQ: PYXS

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development grows, but more slowly than its trailing trend

Q1 FY2026 research & development of $19.6M rose 15.0% year over year, behind the +21.5% change in trailing-twelve-month research & development. Sequentially, it fell 9.7% from the prior quarter. Over 3 fiscal years it compounded at -5.1% a year.

Context

  • Research & development amounted to 531.8% of revenue in FY2025, up 167.9 pp from a year earlier.
  • Research & development increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from +15.0% toward the trailing-twelve-month pace of +21.5%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$19.6M-9.7% QoQ
Last fiscal yearDec 2025
$73.7M+25.4% YoY
LTMMar 2026
$76.25M+21.5% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+15.0%——
1 year+25.4%——
3-year CAGR-5.1%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
73.7M USD
Year-over-year change
+25.4%
4-year CAGR
+9.6%

Research & Development vs competitors

How PYXS compares with its peers on the latest reported figures

  • PYXS's LTM Mar 2026 research & development of $76.25M is the 7th highest of the 10 companies compared; the peer median is $91.32M.
  • Its year-over-year change of +21.5% is the 4th highest of 10, against a peer median of -9.4%.
  • Research & development amounts to 550.2% of revenue for PYXS, versus a peer median of 596.9%.
PYXS Competitors Peer median
Research & Development for PYXS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$10.68B +22061.7%+5.1%—
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026$159.57M +37.4%+18.6%—
VYGRVoyager Therapeutics, Inc.LTM Mar 2026$127.75M -3.1%+30.4%350.1%
CRBUCaribou Biosciences, Inc.LTM Mar 2026$94.52M -28.3%+10.0%843.7%
ENTAEnanta Pharmaceuticals, Inc.LTM Mar 2026$91.32M -20.8%-13.4%131.9%
FHTXFoghorn Therapeutics Inc.LTM Mar 2026$82.1M -9.4%-6.8%290.9%
PYXSPyxis Oncology, Inc.LTM Mar 2026$76.25M +21.5%-5.1%550.2%
HUMAHumacyte, Inc.LTM Mar 2026$73.35M -11.4%+3.1%3638.2%
TNYATenaya Therapeutics, Inc.LTM Mar 2026$62.37M -24.6%-10.1%27721.8%
ZURAZura Bio LimitedLTM Mar 2026$46.35M +48.2%+21.1%—
Peer median (excluding PYXS) $91.32M-9.4%+5.1%596.9%

Competitors are the stored peer set for PYXS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00016.15M13.86M
Cost of Revenue000475K2.39M
Gross Profit00015.67M11.47M
Gross Margin———97.1%82.8%
Research & Development51.05M86.13M49.59M58.75M73.7M
Selling, General & Admin18.66M37.35M32.61M25.42M22.19M
Operating Expenses69.72M123.48M82.2M105.13M95.89M
Depreciation & Amortization647K709K1.93M2.98M4.51M
EBITDA(75.33M)(120.01M)(71.86M)(65.51M)(73.72M)
EBITDA Margin———-405.8%-532.0%
Operating Income(69.72M)(123.48M)(82.2M)(89.46M)(84.42M)
Operating Margin———-554.1%-609.2%
Interest Income23K2.76M6.63M7.04M3.61M
Interest Expense00000
Other Income / Expenses(6.26M)2.76M8.41M9.97M6.19M
Income Before Tax(75.98M)(120.72M)(73.79M)(79.5M)(78.24M)
Pre-Tax Margin———-492.4%-564.5%
Income Tax Expense000(2.16M)1.39M
Net Income(75.98M)(120.72M)(73.79M)(77.33M)(79.62M)
Net Margin———-478.9%-574.5%
EPS (Basic)(2.53)(3.57)(1.85)(1.32)(1.28)
EPS (Diluted)(2.53)(3.57)(1.85)(1.32)(1.28)
Weighted Avg Shares32.22M33.03M39.9M58.45M62.14M
Weighted Avg Shares (Diluted)32.22M33.03M39.9M58.45M62.14M

Pyxis Oncology, Inc.

NASDAQ:PYXS

Intrinsic Alpha fair value

Locked

Current Price

$1.41

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.